Rethinking therapeutic strategies of dual‐target drugs: An update on pharmacological small‐molecule compounds in cancer
Medicinal Research Reviews · 2024-11 · 44 (6) · 2600-2623
DOI: 10.1002/med.22057 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Medicinal Research Reviews, online erschienen am 20.05.2024. Verfasst von Yiren Yang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, and Department of Gastroenterology and Hepatology, West China Hospita…. Hauptthemen laut MEDLINE: Neoplasms, Antineoplastic Agents, Small Molecule Libraries. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 73 Literaturangaben. Gefördert von: National Natural Science Foundation, Key R&D Program of Sichuan Province, Research Foundation for Administration of traditional Chinese Medicine of Sichuan Province.
Abstract (Originalsprache)
Oncogenes and tumor suppressors are well‐known to orchestrate several signaling cascades, regulate extracellular and intracellular stimuli, and ultimately control the fate of cancer cells. Accumulating evidence has recently revealed that perturbation of these key modulators by mutations or abnormal protein expressions are closely associated with drug resistance in cancer therapy; however, the inherent drug resistance or compensatory mechanism remains to be clarified for targeted drug discovery. Thus, dual‐target drug development has been widely reported to be a promising therapeutic strategy for improving drug efficiency or overcoming resistance mechanisms. In this review, we provide an overview of the therapeutic strategies of dual‐target drugs, especially focusing on pharmacological small‐molecule compounds in cancer, including small molecules targeting mutation resistance, compensatory mechanisms, synthetic lethality, synergistic effects, and other new emerging strategies. Together, these therapeutic strategies of dual‐target drugs would shed light on discovering more novel candidate small‐molecule drugs for the future cancer treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, and Department of Gastroenterology and Hepatology, West China Hospital, Sichuan University/West China School of Nursing, Sichuan University…
- Key Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education, School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang, China.
- Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial T…
ORCID-Profile: Bo Liu
Förderung
- National Natural Science Foundation
- Key R&D Program of Sichuan Province
- Research Foundation for Administration of traditional Chinese Medicine of Sichuan Province
- the China Postdoctoral Science Foundation
Zitieren
APA
Yang, Y., Mou, Y., Wan, L. X., Zhu, S., Wang, G., Gao, H., & Liu, B. (2024). Rethinking therapeutic strategies of dual‐target drugs: An update on pharmacological small‐molecule compounds in cancer. Medicinal Research Reviews, 44(6), 2600-2623. https://doi.org/10.1002/med.22057
Vancouver
Yang Y, Mou Y, Wan LX, Zhu S, Wang G, Gao H, et al. Rethinking therapeutic strategies of dual‐target drugs: An update on pharmacological small‐molecule compounds in cancer. Medicinal Research Reviews. 2024;44(6):2600-2623. doi:10.1002/med.22057
BibTeX
@article{Yang2024,
author = {Yang, Yiren and Mou, Yi and Wan, Lin-Xi and Zhu, Shiou and Wang, Guan and Gao, Huiyuan and Liu, Bo},
title = {Rethinking therapeutic strategies of dual‐target drugs: An update on pharmacological small‐molecule compounds in cancer},
journal = {Medicinal Research Reviews},
year = {2024},
volume = {44},
number = {6},
pages = {2600--2623},
doi = {10.1002/med.22057}
}
EUVIMED